Equities analysts expect that Inovalon Holdings Inc (NASDAQ:INOV) will post earnings per share of $0.07 for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Inovalon’s earnings, with estimates ranging from $0.06 to $0.08. Inovalon reported earnings of ($0.04) per share during the same quarter last year, which indicates a positive year over year growth rate of 275%. The business is expected to announce its next quarterly earnings results on Tuesday, May 14th.

On average, analysts expect that Inovalon will report full year earnings of $0.42 per share for the current financial year, with EPS estimates ranging from $0.39 to $0.44. For the next year, analysts anticipate that the business will post earnings of $0.52 per share, with EPS estimates ranging from $0.47 to $0.56. Zacks’ EPS calculations are an average based on a survey of research firms that cover Inovalon.

Inovalon (NASDAQ:INOV) last posted its quarterly earnings data on Wednesday, February 20th. The technology company reported $0.05 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by ($0.02). The firm had revenue of $136.30 million during the quarter, compared to analyst estimates of $145.20 million. Inovalon had a negative net margin of 7.32% and a positive return on equity of 3.88%. Inovalon’s revenue was up 18.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.06 earnings per share.

Several equities research analysts recently weighed in on the company. BidaskClub raised Inovalon from a “hold” rating to a “buy” rating in a report on Wednesday, February 20th. Zacks Investment Research downgraded Inovalon from a “buy” rating to a “hold” rating in a report on Wednesday, January 9th. SunTrust Banks assumed coverage on Inovalon in a report on Friday, February 15th. They set a “buy” rating and a $22.00 price target for the company. ValuEngine raised Inovalon from a “hold” rating to a “buy” rating in a report on Friday, November 30th. Finally, Morgan Stanley raised Inovalon from an “underweight” rating to an “equal weight” rating and increased their price target for the stock from $10.00 to $13.00 in a report on Thursday, December 20th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Inovalon currently has an average rating of “Hold” and an average target price of $15.50.

Shares of INOV stock traded down $0.02 during trading hours on Friday, hitting $12.55. The stock had a trading volume of 828,243 shares, compared to its average volume of 565,371. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 1.40. Inovalon has a twelve month low of $8.90 and a twelve month high of $15.57. The company has a market capitalization of $1.92 billion, a P/E ratio of 69.72, a PEG ratio of 2.66 and a beta of 0.68.

Hedge funds and other institutional investors have recently modified their holdings of the stock. We Are One Seven LLC acquired a new stake in shares of Inovalon during the fourth quarter worth $40,000. Cutler Group LP raised its position in Inovalon by 900.0% in the fourth quarter. Cutler Group LP now owns 6,000 shares of the technology company’s stock worth $85,000 after acquiring an additional 5,400 shares in the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in Inovalon in the fourth quarter worth $160,000. Amalgamated Bank purchased a new position in Inovalon in the fourth quarter worth $146,000. Finally, Oppenheimer Asset Management Inc. purchased a new position in Inovalon in the third quarter worth $108,000. 33.61% of the stock is owned by hedge funds and other institutional investors.

About Inovalon

Inovalon Holdings, Inc, a technology company, provides cloud-based platforms empowering a data-driven transformation from volume-based to value-based models in the healthcare industry. The company's platform enables the assessment and enhancement of clinical and quality outcomes and financial performance.

Read More: SEC Filing

Get a free copy of the Zacks research report on Inovalon (INOV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Inovalon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalon and related companies with MarketBeat.com's FREE daily email newsletter.